The article from the Media Office of Abu Dhabi discusses the Personalised Precision Medicine Programme for Oncology, launched by the Department of Health – Abu Dhabi (DoH). This innovative initiative is making significant strides in providing tailored care to cancer patients in the region.
Launch and Partnerships
The Personalised Precision Medicine Programme for Oncology was launched in October 2022, marking the region’s first such initiative. It is a collaborative effort involving the DoH, Cleveland Clinic Abu Dhabi, G42 Healthcare, and other strategic partners.
Scope and Impact
So far, the programme has provided tailored treatment plans to over 256 Emirati cancer patients in Abu Dhabi. It comprises personalised treatment and prevention plans developed by genetic counsellors and specialists.
Genetic Screening
Eligible patients underwent screening for 47 genes to enhance their clinical care. This genetic screening assists in identifying specific mutations linked to cancers, significantly improving treatment efficiency and patient recovery.
Family Prevention Plans
This programme also extends its reach by including preventive plans for the families of patients who tested positive for inherited gene mutations. Specifically, tailored preventive plans were implemented for 207 family members to help mitigate their cancer risk.
Patient Cohort
Overall, 200 patients aged between 25 and 50 years, selected from the Emirati Genome Programme (EGP), were tested for gene variants associated with higher risks of breast, ovarian, colorectal, and lung cancers. Those identified as high-risk received personalised prevention plans and referrals to specialised clinics for monitoring and intervention.
Future Ambitions
The programme aims to extend beyond oncology and tackle other chronic diseases in the future. The DoH plans to consolidate learnings, unify efforts, and apply innovation and research to advance precision medicine outcomes for various health conditions.
Technological and Research Advancements
The Personalised Precision Medicine Programme for Oncology leverages cutting-edge technologies, including genomic technologies and artificial intelligence, to make gene discoveries, understand molecular pathways, and identify new targets for biomarkers and therapies. This approach aligns with international standards and best practices.
Regulatory and Clinical Guidelines
The DoH has developed regulatory policies and clinical testing guidelines in collaboration with Cleveland Clinic Abu Dhabi. These guidelines are designed to enhance diagnosis, treatment, and prevention strategies, especially for breast and ovarian cancer-associated genes.
Community Impact
Overall, the programme has significantly enhanced treatment efficacy, reduced adverse effects, and provided valuable prognostic insights. It has also helped position Abu Dhabi as a prominent destination for life sciences and innovation in healthcare.
In conclusion, the Personalised Precision Medicine Programme for Oncology in Abu Dhabi represents a transformative advancement in healthcare, focusing on individualized care through genetic profiling, advanced technologies, and collaborative research efforts.
